Pharmaceutical

GLB-001 by GluBio Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval

GLB-001 is under clinical development by GluBio Therapeutics and currently in Phase I for Myelodysplastic Syndrome.

Dec 20, 2023 - 18:00
GLB-001 is under clinical development by GluBio Therapeutics and currently in Phase I for Myelodysplastic Syndrome.
Read the original article

Tags:

Previous Article

GLB-001 by GluBio Therapeutics for Refractory Acute Myeloid Leukemia: Likelihood...

Next Article

UI-059 by Korea United Pharm for Reflux Esophagitis (Gastroesophageal Reflux Dis...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Which drugs are most likely to be approved in Somatic P...

Mar 28, 2024

STAT+: After new cluster, health officials warn mpox could resurge this summer

STAT+: After new cluster, health officials warn mpox co...

May 21, 2023

STAT+: With savvy bets, a dynamic duo makes Eli Lilly one of pharma’s biggest success stories

STAT+: With savvy bets, a dynamic duo makes Eli Lilly o...

Jul 6, 2023